CBP
Showing 1 - 25 of 219
Healthy Adult Subjects Trial in Hefei (Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL), Test drug (T2):
Not yet recruiting
- Healthy Adult Subjects
- Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL)
- +2 more
-
Hefei, Anhui, ChinaThe Second Hospital of Anhui Medical University
Jun 14, 2023
Healthy Volunteer Study Trial in San Antonio (CBP-4888, Placebo)
Recruiting
- Healthy Volunteer Study
- CBP-4888
- Placebo
-
San Antonio, TexasComanche Biopharma Clinical Research Site #1
Jun 1, 2023
Healthy Adult Subjects Trial in Melbourne (CBP-174, Placebo)
Completed
- Healthy Adult Subjects
- CBP-174
- Placebo
-
Melbourne, Victoria, AustraliaNucleus Network Pty Ltd
Aug 9, 2022
Castrate Resistant Prostate Cancer, NUT Carcinoma Trial (EP31670)
Not yet recruiting
- Castrate Resistant Prostate Cancer
- NUT Carcinoma
- (no location specified)
Aug 3, 2022
Healthy Adult Subjects Trial in Suzhou (CBP-307)
Completed
- Healthy Adult Subjects
-
Suzhou, Jiangsu, ChinaConnect Investigative Site
Apr 2, 2022
CBP Versus Non-CBP in Septic Children
Recruiting
- Sepsis
- Children, Only
- CBP
-
Shanghai, Shanghai, ChinaChildren'S Hospital of Fudan University
Jan 10, 2022
Pulmonary Fibrosis, Lung Cancer Trial in Boston ([68Ga]CBP8, PET Imaging)
Recruiting
- Pulmonary Fibrosis
- Lung Cancer
- [68Ga]CBP8
- PET Imaging
-
Boston, MassachusettsMassachusetts General Hospital
Jun 13, 2022
Sleep Disturbance Trial in Hong Kong (Cognitive behavioral prevention program for insomnia (CBP-I))
Not yet recruiting
- Sleep Disturbance
- Cognitive behavioral prevention program for insomnia (CBP-I)
-
Hong Kong, ChinaDepartment of Psychiatry, the Chinese University of Hong Kong
Nov 27, 2023
Pancreatic Cancer Stage IV Trial in United States (CBP501 (16), CBP501 (25), Cisplatin)
Active, not recruiting
- Pancreatic Cancer Stage IV
- CBP501 (16)
- +3 more
-
Tucson, Arizona
- +19 more
Aug 16, 2022
Cardiac Amyloidosis Trial ([68Ga]CBP8 PET/MRI)
Not yet recruiting
- Cardiac Amyloidosis
- [68Ga]CBP8 PET/MRI
- (no location specified)
Nov 9, 2022
Liver Cirrhosis Trial in Bunkyo-Ku (OP-724)
Active, not recruiting
- Liver Cirrhosis
-
Bunkyo-Ku, Tokyo, JapanTokyo Metropolitan Komagome Hospital
Jul 7, 2022
Lung Cancer, Radiation Fibrosis, Radiation Induced Lung Injury Trial in Boston ([68Ga]CBP8)
Recruiting
- Lung Cancer
- +3 more
-
Boston, MassachusettsMassachusetts General Hospital
Jan 18, 2022
Primary Biliary Cholangitis (PBC), Liver Cirrhosis, Biliary Trial in Bunkyo-Ku, Fukuoka (OP-724)
Completed
- Primary Biliary Cholangitis (PBC)
- Liver Cirrhosis, Biliary
-
Bunkyō-Ku, Tokyo, Japan
- +1 more
Jul 4, 2022
Hypertension, Chronic Kidney Disease, Blood Pressure Trial in Montréal (Brachial and Central BP measurements with Mobil-o-Graph
Recruiting
- Hypertension
- +2 more
- Brachial and Central BP measurements with Mobil-o-Graph NG device (IEM), WatchBP Office device (Microlife), BP+ device (Uscom) and Oscar 2 with SphygmoCor inside device (SunTech)
-
Montréal, Quebec, CanadaHôpital du Sacré-Coeur de Montréal
Jul 25, 2023
AN69ST Verse PS in CBP in Septic Children
Not yet recruiting
- Sepsis
- blood purification(PS)
- blood purification(AN69ST)
- (no location specified)
Jan 11, 2023
Ovarian Cancer Trial in Shanghai (Etoposide, Cyclophosphamide, Carboplatin)
Active, not recruiting
- Ovarian Cancer
- Etoposide, Cyclophosphamide, Carboplatin
-
Shanghai, Shanghai, ChinaWu Xiaohua
Jul 25, 2022
Liver Cirrhosis Trial in Bunkyo-Ku (Foscenvivint)
Not yet recruiting
- Liver Cirrhosis
-
Bunkyo-Ku, Tokyo, JapanTokyo Metropolitan Komagome Hospital
Nov 29, 2023
Interstitial Lung Disease Trial in Boston ([68Ga]CBP8, Dotarem)
Recruiting
- Interstitial Lung Disease
-
Boston, MassachusettsMassachusetts General Hospital
Aug 22, 2022
Idiopathic Pulmonary Fibrosis Trial in Boston (PLN-74809, Placebo)
Recruiting
- Idiopathic Pulmonary Fibrosis
- PLN-74809
- Placebo
-
Boston, MassachusettsMassachusetts General Hospital
Nov 14, 2022
HER-2 Positive Breast Cancer Trial in Tianjin (TCbHP VS ddEC-THP)
Recruiting
- HER-2 Positive Breast Cancer
- TCbHP VS ddEC-THP
-
Tianjin, Tianjin, ChinaBreast Oncology, Tianjin Medical University Cancer Institute and
May 15, 2023